MedDevNews, Q2 2022
The effects of the market-wide contraction were seen across multiple metrics in Q2 2022. Public market returns were negative across all verticals, with valuations falling sharply. Most sectors, with the exception oflab diagnostics, infection control & reprocessing, and large diversified, underperformed the S&P 500. CMO M&A transaction activity was down, as were private financings and OEM disclosed value. The number of OEM M&A transactions, however, did manage to increase despite market concerns.